뉴스

Rahul Devraj appointed NIMS Hyderabad Director for three-year term

Dr. Rahul Devraj is among the institute’s senior faculty members and has been associated with its clinical, academic and administrative activities for several years

145 polyclinics rollout along with TIMS Sanathnagar inauguration

The Chief Minister is likely to inaugurate it on June 11, the department of Health is planning to organise handing over of appointment orders to 300 assistant professors and 272 staff nurses, apart from launch of other facilities on that day

MCH incident sparks call for urgent clinical, medical audit of patient care procedures

Public health expert B. Ekbal emphasises that the incident reflects systemic failures rather than the negligence of a single junior staff member. He urges the Health dept. to implement robust monitoring protocols to ensure patient safety.

Sightsavers India opens 2026 fellowship for ophthalmologists

The 18-month programme is designed to equip early-career ophthalmologists with advanced clinical, surgical, and leadership skills while preparing them to deliver quality eye care in areas of high need

Jayadeva plans weekly heart screening clinics in Chamarajanagar, eyes satellite cardiac unit

Kerala mulls boosting stroke treatment network via hub-and-spoke model

Replying to a calling attention motion, Health Minister says post-COVID stroke cases are generally on the rise in the State. But more clinical studies are required to establish the reasons behind this

TGMC uncovers unqualified dentists and homeopathy doctors treating skin ailments at Hyderabad clinic

Virat, Anushka dance at RCB's championship after party: 'One felt nice, we did twice' | Video

The couple joined the jubilant festivities alongside teammates, support staff, and family members. RCB secured back-to-back IPL titles by completing a clinical chase of 156 and defeating the Gujarat Titans by five wickets at the Narendra Modi Stadium on Sunday.

Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details

Shares of Wockhardt soared as much as 19% to their day's high of Rs 2,420 on the BSE on Monday after the company announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (UTI), including pyelonephritis, caused by susceptible Gram-negative pathogens.According to the company, ZAYNICH combines the fourth-generation cephalosporin cefepime with zidebactam and is designed to target multiple penicillin-binding proteins simultaneously. The antibiotic had earlier received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.The approval comes at a time when antimicrobial resistance remains a major healthcare challenge. Wockhardt cited data indicating that more than 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in over 35,000 deaths each year. The company also noted that complicated urinary tract infections account for more than 6,00,000 hospitalisations annually in the U.S., with a growing proportion linked to antimicrobial-resistant and multidrug-resistant bacteria.The FDA's decision was based in part on results from the Phase 3 ENHANCE-1 study, a randomised, double-blind, multicentre trial that evaluated the efficacy, safety and tolerability of ZAYNICH against meropenem in hospitalised adults with complicated urinary tract infections or acute pyelonephritis.In the study, ZAYNICH achieved a composite clinical cure and microbiological response rate of 89% at the test-of-cure visit, compared with 68.4% for meropenem. The treatment difference was 20.6% with a 95% confidence interval of 12.3 to 29.5. The company said the drug was generally well tolerated during the trial.The ENHANCE-1 study enrolled 530 patients across 64 sites spanning the United States, Europe, Latin America, China and India.Wockhardt stated that ZAYNICH targets penicillin-binding proteins PBP 1a/b, 2 and 3 simultaneously, a mechanism that it says provides bactericidal activity against multidrug-resistant Gram-negative bacteria for which treatment options remain limited.The company also disclosed that ZAYNICH received approval from the Drugs Controller General of India (DCGI) on May 27, 2026. In addition, Wockhardt has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for the antibiotic.Sensex, Nifty today: Catch all the LIVE stock market action here (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Virat Kohli's dhol dance with Pandya goes viral after RCB's IPL 2026 title triumph

Royal Challengers Bengaluru secured their second consecutive IPL title by defeating Gujarat Titans. Star batter Virat Kohli and all-rounder Krunal Pandya celebrated the historic win with dhols. Kohli's unbeaten 75 guided RCB to a clinical chase. This victory makes RCB the third franchise to defend their IPL crown. Kohli was named Player of the Match for his exceptional performance.

2 mainboard IPOs set to hit D-Street after a month of lull

India's primary market is set for an active week in the mainboard segment, with two public issues scheduled to open for subscription even as investor sentiment remains selective amid volatile equity markets and heightened global uncertainty. The spotlight will be on the IPOs of CMR Green Technologies and Hexagon Nutrition, which together aim to raise nearly Rs 770 crore.The offerings come at a time when the IPO market has seen a lull for a few weeks in a tepid 2026. While several companies have secured regulatory approvals in recent weeks, many have put off their IPO plans due to market volatility.The first issue to hit the market next week will be CMR Green Technologies. The company's IPO will open on June 3 and close on June 5. The issue is priced in the range of Rs 182-192 per share and aims to raise Rs 630.9 crore. Equirus Capital is managing the offering.CMR Green Technologies operates in the metal recycling and circular economy segment, manufacturing recycled aluminium and zinc products for automotive and industrial applications. The company counts several leading automotive manufacturers among its customers and is positioned to benefit from increasing adoption of recycled metals and sustainability-focused manufacturing practices.The company is expected to attract investor interest given the growing focus on resource efficiency, electric vehicles and environmental regulations that are encouraging the use of recycled materials.The second mainboard issue scheduled for next week is Hexagon Nutrition.The IPO will open on June 5 and close on June 9. The company has fixed a price band of Rs 42-45 per share and plans to raise Rs 138.9 crore through an offer for sale of 3.09 crore shares. Since the issue is entirely an OFS, the company will not receive any proceeds from the public offering.Hexagon Nutrition is a research-driven nutrition company engaged in manufacturing micronutrient premixes, wellness and clinical nutrition products, therapeutic formulations and ready-to-use nutritional foods.Founded in 1993, the company operates manufacturing facilities in Maharashtra, Tamil Nadu and Uzbekistan and exports products to more than 75 countries. Its products are sold through both business-to-consumer and business-to-business channels and include brands such as Pentasure, Obesigo, Pediagold and Nutrone.The company has reported steady financial growth in recent years. Profit after tax rose to Rs 24.4 crore in FY25 from Rs 12.2 crore in FY24 and Rs 5.8 crore in FY23, while total income increased to Rs 331 crore.At the upper end of the price band, Hexagon Nutrition is valued at around 15 times post-issue earnings.Market participants will closely watch subscription trends in both issues as they could provide a signal on investor appetite for new listings after months of fluctuating market sentiment.The broader market environment remains mixed. Indian equities have faced pressure this year from elevated crude oil prices, geopolitical tensions in West Asia and foreign institutional investor outflows. However, strong domestic liquidity and continued retail participation have helped support primary market activity.SME segmentApart from the mainboard issues, the SME segment is also expected to remain active next week.Genxai Analytics plans to raise about Rs 55 crore through its NSE SME IPO, which opens on June 5 and closes on June 9. The issue is priced at Rs 110-116 per share. Vahh Chemicals will launch a fixed-price SME issue worth Rs 13.5 crore between June 4 and June 8 on the BSE SME platform.Merritronix will also tap the SME market with a Rs 70 crore issue opening on June 1 and closing on June 3.While SME offerings continue to attract investor interest, listing performance has remained mixed in recent months, making subscription quality and valuation discipline increasingly important factors for investors.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic

Wockhardt shares rallied sharply on Friday, surging 7.87% to hit Rs 1,910.50 after the pharmaceutical company received a major regulatory boost for its breakthrough antibiotic, Zaynich. Notably, the stock has climbed nearly 12% in just the last two trading sessions, reflecting strong investor optimism following the development.In an exchange filing, Wockhardt announced that the Central Drugs Standard Control Organisation (CDSCO) has approved the import and marketing of its indigenously discovered and developed first-in-class antibiotic, Zaynich (Zidebactam/Cefepime), in India.The approval covers the treatment of adult patients suffering from complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases involving concurrent Gram-negative bacteremia.The nod is backed by strong results from the pivotal ENHANCE-1 Phase 3 clinical trial, a multinational, randomised, double-blind study comparing Zaynich with Meropenem — one of the widely used antibiotics for severe infections.The results significantly favoured Zaynich. The study showed that 89% of patients treated with Zaynich achieved clinical cure and microbiological eradication, compared with 68.4% in the Meropenem arm, delivering a treatment advantage of 20.6%.Even more striking were the outcomes in high-risk bacteremia patients, where Zaynich posted an 89% response rate versus just 44% for Meropenem, highlighting its potential as a game-changing therapy in severe drug-resistant infections.The company stated that Zaynich could emerge as a critical weapon against carbapenem-resistant infections — an area where existing treatment options like colistin and polymyxins often face limitations due to toxicity and weaker efficacy. Importantly, the drug is designed to combat metallo-β-lactamase (MBL)-mediated resistance, one of the toughest and most widespread antibiotic resistance mechanisms in India.Wockhardt Shares: Price trend and technical outlookWockhardt shares have surged nearly 27% over the past month, while the stock has skyrocketed an astounding 946% in the last three years, turning investor wealth nearly 10-fold during the period. The company currently commands a market capitalisation of around Rs 28,777 crore.On the technical front, Trendlyne data indicates that Wockhardt’s 14-day Relative Strength Index (RSI) stands at 72.3. An RSI above 70 is generally considered overbought, suggesting the stock could witness some profit-booking or a short-term pullback after the recent sharp rally.However, the overall trend remains firmly bullish, with the stock trading above all 8 out of 8 key simple moving averages (SMAs), indicating sustained strength in momentum.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)